Related by context. All words. (Click for frequent words.) 79 Meets Primary Endpoint 78 Drug Candidate 77 Investigational Treatment 77 Phase 2b Trial 77 Prolongs Survival 76 Phase 2b Clinical Trial 76 Patients Receiving 76 Tyrosine Kinase Inhibitor 76 Chronic Sinusitis 76 Overactive Bladder 76 Treating Chronic 75 Mouse Model 75 Antitumor Activity 75 Advanced Melanoma 75 Allergic Rhinitis 75 Investigational Compound 75 Novel Oral 75 Adjuvant Chemotherapy 75 Transdermal Patch 75 Patients Treated With 75 Atopic Dermatitis 75 FDA Approvals 75 Hypercholesterolemia 74 Combo Therapy 74 Receives Orphan Drug Designation 74 Adjunctive Therapy 74 Pulmonary Arterial Hypertension 74 Demonstrates Significant 74 Diabetic Foot Ulcer 74 Controlled Trial 74 Initiate Clinical Trial 74 Benign Prostatic Hyperplasia 74 acetonide FA 74 Transdermal Delivery 74 Oral Mucositis 74 Preclinical Study 74 Catheter Associated 74 Completes Patient Enrollment 74 Present Preclinical Data 74 Rheumatoid Arthritis Patients 74 Fungal Infections 74 Single Dose 74 Phase IIb Clinical Trial 74 Improves Survival 74 Oral Fingolimod 74 Initiates Clinical Trial 73 Combination Treatment 73 Recombinant Human 73 Improves Outcomes 73 ACE Inhibitors 73 Shows Promise Against 73 Severe Sepsis 73 Combination Therapy 73 Demonstrates Efficacy 73 Submits NDA 73 Zorbtive TM 73 Treated Patients 73 Secondary Hyperparathyroidism 73 Clinical Outcome 73 Metabolic Disorder 73 Chronic Bronchitis 73 Retinoic Acid 73 JAK Inhibitor 73 Pooled Analysis 73 Allogeneic 73 Therapeutic Potential 73 Prospective Randomized 73 Phase IIb Trial 73 Diabetic Nephropathy 73 Fracture Risk 73 Successfully Completes Phase 73 Replacement Therapy 73 Decitabine 73 Phase 2b Study 73 Knee Osteoarthritis 73 Mycophenolate Mofetil 73 FDA Okays 73 Treatment Resistant 73 Orally Active 73 Complicated Skin 73 Gastric Cancer 73 Ischemic 73 Cardiotoxicity 73 Parathyroid Hormone 73 Renal Cell Carcinoma 73 Survival Benefit 73 Preclinical Data 72 Fingolimod 72 Hepatocellular Carcinoma 72 Novel Mechanism 72 Previously Treated 72 Well Tolerated 72 Dual Antiplatelet Therapy 72 beta 1a 72 Recurrent Breast Cancer 72 Drug Shows Promise 72 Lupus Nephritis 72 Epidermal Growth Factor Receptor 72 Microplasmin 72 See CLINICAL PHARMACOLOGY 72 Initiates Phase III 72 Treatment Reduces 72 Shows Efficacy 72 Anti Tumor 72 Kinase Inhibitor 72 Demonstrates Positive 72 Parnate 72 Improve Survival 72 Immune Responses 72 Gene Linked 72 Clinical Trial Data 72 Protease Inhibitors 72 Inflammatory Diseases 72 Investigational Agent 72 Septic Shock 72 Study Evaluating 72 Peripheral Arterial 72 Proven Effective 72 Presents Preclinical Data 72 Aliskiren 72 Breast Cancer Recurrence 72 Myelodysplastic Syndrome MDS 72 Is Well Tolerated 72 Dendritic Cells 72 Skeletal Muscle 72 Schizophrenia Treatment 72 Paraplatin ® 72 Phase IIa Clinical Trial 72 Pediatric Patients 72 Initiates Phase II 72 Renal Function 72 Soft Tissue Sarcoma 72 Slow Progression 72 Patients Undergoing 72 Double Blind Placebo 72 HDAC Inhibitor 72 Drug Combo 72 Clinical Trial Results 72 Antifungal 72 Statistically Significant 72 Renal Anemia 72 Proves Effective 72 Polyneuropathy 72 Aurora Kinase 72 Phase III Clinical Trial 72 Rheumatoid 72 Diabetic Peripheral Neuropathy 72 Inhaled Corticosteroids 71 HCV Protease Inhibitor 71 NDA Submission 71 Tezampanel 71 Cholesterol Lowering Drug 71 Newly Diagnosed Multiple Myeloma 71 lexidronam injection 71 Beta Blocker 71 IND Application 71 Minimally Invasive Treatment 71 Pivotal Phase III 71 Placebo Controlled Trial 71 Tyrosine Kinase Inhibitors 71 Levels Linked 71 Kidney Function 71 Progressive Multifocal Leukoencephalopathy 71 Interferon Beta 71 Subtypes 71 Adjuvant Treatment 71 Cell Transplants 71 Genes Linked 71 Tiotropium 71 Generalized Anxiety Disorder 71 Investigational Drug 71 Adipose Derived Stem Cells 71 Phase 2a Trial 71 Achieves Primary Endpoint 71 Liver Failure 71 Inflammatory Markers 71 Etanercept 71 Shows Promising 71 Immunotherapeutic 71 #-# Full Text 71 Naive Patients 71 Potent Inhibitor 71 Reduced Risk 71 Antiangiogenic 71 Hypertensive Patients 71 Protease Inhibitor 71 Fabry Disease 71 Tigecycline 71 Thiazolidinediones 71 Drug Prevents 71 Percutaneous Tibial Nerve Stimulation 71 Chronic Prostatitis 71 GW# [003] 71 Angioedema 71 Patients Suffering 71 Patients Treated 71 Demonstrates Potential 71 Severe Asthma 71 abacavir Ziagen 71 Mg Uk 71 Elderly Patients 71 Effective Treatments 71 treat benign prostatic 71 Neovascular Age Related Macular 71 Progenitor Cells 71 Pharmacokinetic Study 71 uricase 71 Vaccine Adjuvant 71 Stress Incontinence 71 Protein Linked 71 Attenuates 71 Mg Usa 71 Clinical Trial Evaluating 71 Antiviral Therapy 71 Slows Progression 71 Inflammatory Arthritis 71 Treatment Shows Promise 71 Hormone Receptor Positive 71 Initiates Clinical 71 Long Term Efficacy 71 Granted Orphan Drug 71 Relapsing Multiple Sclerosis 71 diarrhea predominant irritable 71 Thrombotic 71 Chronic Constipation 71 Improved Survival 71 Confirms Efficacy 71 C1 Inhibitor 71 Tumor Necrosis Factor 71 Asthma COPD 71 Epratuzumab 71 Gene Mutation 71 Diabetic Foot Ulcers 71 Myoblast 71 metastatic malignant 71 Initiate Phase 71 Bone Metastases 71 Randomized Double blind 71 Receptor Antagonists 71 Taxane 71 Immunosuppressant 71 Chronic Hepatitis B 71 Factor Receptor 71 Hepatitis C Genotype 71 Peginterferon 71 Therapy Improves 70 Lowers Risk 70 Postmenopausal Osteoporosis 70 Pafuramidine 70 Reduces Mortality 70 Valopicitabine 70 Fondaparinux 70 Antiplatelet 70 Angiogenic 70 Melphalan 70 Enlarged Prostate 70 Receptor Agonist 70 Aflibercept 70 Prophylactic Treatment 70 Acute Heart Failure 70 Non Alcoholic Fatty 70 Systemic Delivery 70 Bosutinib 70 Pharmacokinetics PK 70 Preclinical Models 70 Beneficial Effects 70 Phase Ib Clinical Trial 70 Files IND 70 hypereosinophilic syndrome 70 Advanced Pancreatic Cancer 70 Bazedoxifene 70 Chronic Heart Failure 70 Teriparatide 70 Intravesical 70 Enzyme Replacement Therapy 70 Prodrug 70 Chronic Renal Failure 70 Anti Tumor Activity 70 Effectively Treats 70 Heart Failure Patients 70 Receptor Antagonist 70 AVAPRO 70 HER2 Positive Breast Cancer 70 Chronic Hepatitis C 70 Teva Provides Update 70 Disease Modifying 70 Resistant Hypertension 70 Vidaza azacitidine 70 Hepatitis C Virus 70 Appears Safe 70 Lung Cancer Drug 70 TNF Tumor Necrosis Factor 70 thalidomide Thalomid 70 Sustained Release 70 Lymphoid 70 Advanced Renal Cell 70 Neuroprotective Effects 70 Novel Compound 70 Novel Antibiotic 70 Adult Stem Cell Therapy 70 Genital Herpes 70 Initiates Enrollment 70 Trandolapril 70 complement inhibitor eculizumab 70 Chemotherapeutic Agents 70 Pegylated Interferon 70 Chemotherapy Induced 70 Demonstrates Potent 70 Phase 2a Clinical Trial 70 Hepatic Encephalopathy 70 Statin Drugs 70 Small Intestine 70 Oral Insulin 70 Inhibits 70 Diabetic Patients 70 Non Alcoholic Steatohepatitis 70 FDA APPROVES 70 Adjunctive 70 Completes Enrollment 70 Prevent Stroke 70 Antithrombin 70 Tumor Response 70 Idiopathic Pulmonary Fibrosis 70 Ketorolac 70 Malignant Glioma 70 Beta Blockers 70 Heart Transplant Recipients 70 Randomized Phase 70 Lubiprostone 70 Bipolar Mania 70 Antitumor 70 Acute Ischemic Stroke 70 Brain Metastases 70 Presents Positive 70 Phase III Trial 70 Peptic Ulcer 70 Virus Infection 70 Unresectable 70 TNF Blockers 70 chronic idiopathic thrombocytopenic purpura 70 Metastatic Melanoma 70 Diabetic Neuropathic Pain 70 Lupus Drug 70 Natalizumab 70 Estrogen Receptor 70 Gout Drug 70 Radiofrequency Ablation 70 Osteoporosis Drug 70 Anticancer Agent 70 Cinacalcet 70 Liver Injury 70 Pemetrexed 70 Malignant Melanoma 70 Genes Identified 70 Refractory Hodgkin Lymphoma 70 Controlled Study 70 Hormone Refractory Prostate Cancer 70 Contrast Agent 70 Montelukast 70 R Saizen R 70 humanized monoclonal 70 Demonstrated Significant 70 Epoetin Alfa 70 Obese Patients 70 Intravitreal 70 Relapsed Refractory 70 Epilepsy Drug 70 Anti Inflammatory 70 INTEGRILIN R 70 Efficacious 70 Dose Ranging Study 70 Dehydrogenase 70 Medoxomil 70 Patient Enrollment 70 Squamous 70 Disease Progression 70 Initiates Clinical Trials 70 Myocardial Ischemia 70 Nilotinib 70 AA Amyloidosis 70 Effective Than 70 Double Blind Randomized 69 Oral Spray 69 Systemic Sclerosis 69 Interferon Alfa 69 Chronic Wounds 69 Therapeutic Efficacy 69 Plaque Psoriasis 69 Mimetics 69 transthyretin TTR mediated amyloidosis 69 Increased Mortality 69 Left Ventricular 69 Primary Hypercholesterolemia 69 Orally administered 69 familial amyloidotic polyneuropathy FAP 69 Bicalutamide 69 Nicotine Vaccine 69 Successfully Treated 69 Tumor Targeting 69 Psoriasis Patients 69 Glucocorticoid 69 Diastolic Heart Failure 69 Allergic Asthma 69 Hyperlipidemia 69 ST Elevation Myocardial 69 Prostate Cancer Patients 69 Dupuytren Contracture 69 Lung Injury 69 Denufosol 69 Immunomodulatory 69 Blood Pressure Drug 69 Treatment Regimen 69 ORENCIA ® 69 Study Demonstrates 69 Glatiramer Acetate 69 Intravenous Formulation 69 Platinol ® 69 vinorelbine tartrate 69 Fluconazole 69 FDA Accepts 69 PRIALT 69 Hsp# Inhibitor 69 Androgen Receptor 69 ALN HPN 69 Safinamide 69 Muscle Wasting 69 Topical Treatment 69 Commercialize Novel 69 Efficacy Trial 69 Autoimmune Disease 69 Kepivance 69 methylnaltrexone bromide 69 Metastatic Colorectal Cancer 69 Immune Mediated 69 Polymorphisms 69 Chronic HCV 69 Functional Dyspepsia 69 Hematopoietic 69 Darbepoetin Alfa 69 Kinase Inhibitors 69 Genes Involved 69 Phase III Pivotal 69 Psoriatic Arthritis 69 Irritable Bowel 69 Anticancer Activity 69 Leukemias 69 Bisphosphonate 69 Endovascular Treatment 69 Vaprisol 69 Liprotamase 69 Budesonide 69 Minimally Invasive Procedure 69 Vascular Dementia 69 Endometrial Cancer 69 Periodontal Disease 69 Myelodysplastic Syndromes 69 Epstein Barr Virus EBV 69 Meta Analysis 69 Metabolic Disease 69 II Clinical Trial 69 alfuzosin 69 Lymphocytic 69 Adefovir 69 Shows Statistically Significant 69 Novel Small Molecule 69 Iron Overload 69 CYT# potent vascular disrupting 69 Cholesterol Lowering 69 Potent Anti 69 Randomized Double Blind 69 Maribavir 69 Anthracycline 69 Calcitonin 69 Migraine Headaches 69 vapreotide acetate 69 Aerosolized 69 Cutaneous T 69 Irinotecan 69 FDA Clears 69 chronic eosinophilic leukemia 69 Bronchodilator 69 Kuvan sapropterin dihydrochloride 69 myelodysplastic myeloproliferative diseases 69 Drug Resistant 69 Urinary Tract Infections 69 Treat Parkinson Disease 69 Novel Treatments 69 Hepatotoxicity 69 Ropinirole 69 Phase III Trials 69 Oral Formulation 69 Pegloticase 69 Inhaled Liposomal Ciprofloxacin 69 Azathioprine 69 Peginterferon Alfa 2a 69 Milestone Payment 69 Randomized Double Blind Placebo 69 Cilostazol 69 Myelofibrosis 69 Enzastaurin 69 Nesiritide 69 Insulin Resistance 69 Confirmatory Phase 69 Ischemic Stroke 69 Therapeutic Vaccine 69 Metastatic Prostate Cancer 69 Osteoporosis Treatment 69 Renal Artery 69 Diagnostic Criteria 69 Presents Preclinical 69 Postmenopausal Women 69 Oncolytic 69 B Cell Lymphoma 69 Breast Cancers 69 Nebulized 69 Significantly Reduces 69 Systemic Lupus Erythematosus 69 Elagolix 69 Cannabinoid 69 VAPRISOL 69 Atypical Antipsychotic 69 ThermoDox R 69 Anticancer Drugs 69 Fast Track Status 69 Study Showed 69 Immunosuppression 69 Blocked Arteries 69 Dacogen decitabine 69 Golimumab 69 Orthostatic Hypotension 69 Suicidality 69 HeFH 69 denileukin diftitox 69 Iron Deficiency Anemia 69 Initiates Dosing 69 Tumor Growth 69 Test Detects 69 Viral Load 69 Chemokine Receptor 69 Venous Thromboembolism 69 Skin Disorders 69 Tumor Suppressor 69 Skin Lesions 69 Low Dose 69 Lanthanum Carbonate 69 topical calcineurin inhibitors 69 Mitral Regurgitation 69 Acute Renal Failure 69 Signaling Pathway 68 Subgroup Analysis 68 Gum Disease 68 Extended Release 68 Potent Antiviral Activity 68 Coronary Arteries 68 Sapacitabine 68 Sevelamer 68 Danazol 68 Bronchiectasis 68 Oxybutynin 68 Respiratory Distress 68 Vaccine Protects Against 68 Radiofrequency Ablation RFA 68 cromolyn sodium 68 J Am Coll 68 Prospective Multicenter 68 Bucindolol 68 Glatiramer acetate 68 Inhalation Solution 68 Rhinitis 68 Fibroblast 68 Antifungals 68 Pramlintide 68 Generic Versions 68 Androgen 68 Hepatitis B Vaccine 68 Ecallantide 68 benign prostatic hypertrophy BPH 68 Begins Dosing 68 Degarelix 68 Predict Risk 68 Hospital Acquired Pneumonia 68 Preclinical Efficacy 68 Hormone Therapy 68 Mucositis 68 HER2 Positive 68 Medication Errors 68 Develop Novel 68 Mouse Models 68 Invasive Breast Cancer 68 Mylan Receives Approval 68 Autologous Stem Cell Transplantation 68 Telaprevir VX 68 vaginal candidiasis 68 P#Y# [001] 68 Atomoxetine 68 Adenoma 68 Significantly Improves 68 Gene Variant 68 Itraconazole 68 Erythropoietic 68 Androgen Deprivation Therapy 68 Fludara ® 68 Reduces Pain 68 Interferon Gamma 68 Maven Semantic 68 Inhaled Nitric Oxide 68 Randomized Study 68 HCV Genotype 68 Renal Impairment 68 Regenerative Cells 68 Prolongs Life 68 Adjuvant Therapy 68 Immunologic 68 Fluorouracil 68 EVIZON TM 68 Predict Response 68 Teriflunomide 68 First Patient Dosed 68 FS Antihemophilic Factor Recombinant 68 FASLODEX 68 Anti VEGF 68 Interferon Alpha 68 Azacitidine 68 Therapeutic Antibody 68 Uric Acid 68 Gets FDA Clearance 68 dual endothelin receptor antagonist 68 Clostridium difficile Infection 68 Bipolar Depression 68 Randomized Clinical Trial 68 Nitazoxanide 68 Pegylated 68 Mitoxantrone 68 Proteasome 68 Serious Infections 68 personalized cellular immunotherapy 68 Methylnaltrexone 68 Lenocta 68 Systematic Review 68 Pivotal Trials 68 alefacept 68 Adenoviral 68 See WARNINGS 68 R lenalidomide 68 5 Fluorouracil 68 Showed Significant 68 Sustained Efficacy 68 BUPHENYL R 68 Cytarabine 68 Dose Response 68 NMDA antagonist 68 Anticoagulants 68 Small Molecule 68 Novel Inhibitor 68 Pelvic Organ Prolapse 68 Capecitabine 68 MetroGel 68 Captopril 68 Aortic Stenosis 68 Granulocyte Colony Stimulating Factor 68 adalimumab Humira 68 Advanced Prostate Cancer 68 Clinical Efficacy 68 NICE Recommends 68 Leucovorin 68 Intravenous immunoglobulin 68 Antiviral Drugs 68 Diuretic 68 metastatic neuroendocrine tumors 68 Serostim ® 68 Pazopanib 68 Lung Cancer Patients 68 Spinal Manipulation 68 Breast Cancer Cells 68 Growth Hormone Deficiency 68 estrogen receptor antagonist 68 Oral Calcitonin 68 Patient Outcomes 68 Squalamine 68 Chronic Rhinosinusitis 68 Novel Therapeutic 68 Tolerability 68 Atypical Antipsychotics 68 Drug Fails 68 Conjugate 68 etanercept Enbrel 68 Artery Disease 68 Friedreich Ataxia FRDA 68 Diabetic Retinopathy 68 Premenopausal Women 68 Portal Hypertension 68 MTP inhibitor 68 Benign Prostatic Hyperplasia BPH 68 LAB CGRP 68 Combination REOLYSIN R 68 Hepatocellular 68 overactive bladder syndrome 68 KL4 Surfactant 68 Fibrates 68 Angiotensin Converting Enzyme 68 Receives Approvable Letter 68 Bevacizumab 68 Ozarelix 68 Trial Evaluating 68 BCG refractory carcinoma 68 Botulinum Toxin 68 Alprostadil 68 Multiple Myeloma Patients 68 Viral Infections 68 Gene Variants 68 Therapy Reduces 68 Genes Associated 68 RhuDex 68 Angiotensin II 68 Thrombus 68 erythematosus 68 Reflux Disease 68 biliary tract cancer 68 Chronic Myeloid Leukemia 68 Hypotension 68 Anticoagulant 68 Psoriasis Drug 68 Newly Diagnosed 68 Morquio 68 aurora kinase 68 Liver Metastases 68 Commences Phase 68 Non Invasive Treatment 68 prucalopride 68 Autoimmune Diseases 68 Dasatinib 68 Placebo Controlled Study 68 Metabolic Endocrinology 68 Progenitor Cell 68 Losartan 68 Diagnostic Tests 68 Keratitis 68 Vaginal Gel 68 Monoclonal Antibody 68 Topical Cream 68 Insulin Glargine 68 Miconazole 68 Monotherapy 68 Rheumatoid Arthritis Drug 68 FDA Approves Drug 68 CIMZIA TM certolizumab pegol 68 Randomized Phase II 68 Saforis 68 Chemoradiation 68 Pivotal Study 68 Premature Infants 68 Thrombin 68 alpha1 proteinase inhibitor 68 Mitomycin C 68 Neoadjuvant Chemotherapy 68 Valvular Heart Disease 68 Community Acquired Pneumonia 68 pregabalin Lyrica 68 acute intermittent porphyria 68 Prostate Cancer Vaccine 68 Neoplasms 68 HuMax 68 Doripenem 68 Romidepsin 68 fosbretabulin 68 Corneal Transplant 68 Surgical Procedures 68 Bacterial Vaginosis 68 ST Segment Elevation 68 Liposomal 68 Pemphigus 68 Often Misdiagnosed 68 inhalation powder 68 Genetic Predisposition 68 Factor VIIa 68 Vaccine Candidate 68 Acute Bacterial Sinusitis ABS 68 Thromboembolic 68 Differential Diagnosis 68 aripiprazole Abilify 68 Multicenter Randomized Double 68 Unfractionated Heparin 68 gabapentin Neurontin 67 Frozen Shoulder Syndrome 67 Tolvaptan 67 Telithromycin 67 Cethromycin 67 ziconotide 67 Immune Cells 67 lichen planus 67 Glufosfamide 67 Atypical Hemolytic Uremic Syndrome 67 Severe Acne 67 Renal Cancer 67 PEGylated Fab fragment 67 Rotavirus Vaccine 67 Valsartan 67 Aortic Valve 67 Adalimumab 67 Thromboembolism 67 Reports Preclinical Data 67 Contrast Agents 67 oral prodrug 67 Antisense Drug 67 Blepharospasm 67 Sipuleucel T 67 Cocaine Addiction 67 Moxifloxacin 67 Oral Cladribine 67 Stem Cell Treatment 67 Transthyretin 67 Acute Exacerbations 67 Initiates Phase 67 Pivotal Phase 67 intranasal formulation 67 Critical Limb Ischemia CLI 67 Inflammatory Pain 67 Antigen Specific 67 Numoisyn Liquid 67 Significantly Reduced 67 Reduces Risk 67 Anti Inflammatory Drug 67 constipation OIC 67 Emerging Therapies 67 Candidiasis 67 Dose Escalation 67 Reductase 67 XOPENEX R 67 Hepatitis B Virus 67 Erosive Esophagitis 67 Remission Maintenance 67 Molecular Basis 67 MEDICATIONS 67 Solid Tumors 67 Topical Gel 67 Catheter Ablation 67 Efficacy Results 67 SPRYCEL ® 67 Kidney Failure 67 Hemodialysis Patients 67 BUPHENYL 67 Stent Placement 67 Vitrasert R 67 Hydralazine 67 Polymerase Inhibitor 67 Bepreve TM 67 Demonstrate Significant 67 pan HDAC inhibitor 67 treat chronic sinusitis 67 Receives Orphan Drug 67 Ridaforolimus 67 Phase III Clinical Trials 67 ergot derivatives 67 Oral Cavity 67 Node Positive 67 Infected Patients 67 Myeloma Patients 67 phosphodiesterase inhibitor 67 Diabetic Macular Edema 67 J Clin 67 Symptom Relief 67 Cardiovascular Events 67 Stomatitis 67 Randomized Controlled 67 conivaptan 67 Kidney Transplant Patients 67 Suppositories 67 topically administered 67 Disease IBD 67 Pharmacodynamics 67 Chronic Myelogenous Leukemia 67 Posaconazole 67 Intracerebral Hemorrhage 67 Fewer Side Effects 67 Pneumococcal Vaccine 67 nucleoside analog 67 Otitis Media 67 Pegylated Liposomal Doxorubicin 67 Irritable Bowel Syndrome IBS 67 Soriatane 67 nimodipine 67 RezularTM 67 Occlusive Disease 67 Heterozygous Familial Hypercholesterolemia 67 #mg Tablets [002] 67 Invasive Fungal Infections 67 Low Doses 67 Intrathecal 67 Vulvar 67 Epithelial 67 Cervical Dystonia 67 CLINICAL PHARMACOLOGY 67 Lowers Blood Pressure 67 Ziprasidone 67 Arterial Disease 67 Acute Coronary Syndromes 67 Systemic Lupus Erythematosus SLE 67 Tacrolimus 67 Castration Resistant Prostate Cancer 67 Hypertriglyceridemia 67 Refractory Angina 67 Febuxostat 67 Treatment Naïve Patients 67 Deforolimus 67 Estrogen Therapy 67 Omalizumab 67 Maleate 67 Colorectal Cancer Patients 67 Retinal Vein Occlusion 67 Stomach Cancer 67 Abstract Accepted 67 Zoledronic Acid 67 reflux disease GERD 67 topically applied SEPA 67 Antihistamine 67 Urine Test 67 Genetic Variation 67 ISTODAX ® 67 Uterine Fibroids 67 Demonstrates Statistically Significant 67 Lung Cancer Survival 67 Neoadjuvant 67 Hepatic 67 Modulates 67 recurrent glioblastoma multiforme 67 Indomethacin 67 Non Responders 67 Interferon beta 1a 67 Analgesic 67 Partial Onset Seizures 67 Successfully Treats 67 leiomyomas 67 Taclonex R 67 Acute Pancreatitis 67 Physician Insights 67 ANN INTERN MED 67 Oropharyngeal Candidiasis 67 Inhaled Insulin 67 Chronic Pelvic Pain 67 Spectrum Pharmaceuticals Announces 67 Galantamine 67 Immune Therapy 67 PRN FDA Approves 67 PEGylated anti 67 Improve Outcomes 67 Randomized Controlled Trials 67 Hydrochloride Injection 67 Myocardial Perfusion Imaging 67 targeted antifolate 67 Anemia Drug 67 Significantly Improved 67 Randomized Evaluation 67 Prostatic 67 Fatty Liver 67 Receive Milestone Payment 67 Prognostic Value 67 Xyfid TM 67 gefitinib Iressa 67 Postherpetic Neuralgia 67 HCl Injection 67 Levoleucovorin 67 Cyclosporine 67 Carotid Stenting 67 Autoimmune Disorders 67 Neovascularization 67 Hyaluronidase 67 Carotid 67 Cardiovascular Disease Risk 67 nortriptyline Pamelor 67 Obesity Linked 67 investigational oral inhibitor 67 PKC# 67 icatibant 67 histone deacetylase inhibitor 67 Cytotoxicity 67 Hyperuricemia 67 Lung Tumors 67 Launches Generic Version 67 venlafaxine Effexor 67 Data Suggest 67 TAXOTERE R 67 Diabetes Hypertension 67 Epoetin 67 Genes Predict 67 Insulin Sensitivity 67 Simulect 67 Randomized Controlled Trial 67 hyperprolactinemia 67 Eltrombopag 67 Alternative Treatments 67 Migraine Drug 67 CNS Disorders 67 Sinus Infections 67 Candesartan 67 Cethrin R 67 Stress Urinary Incontinence 67 Neuroprotection 67 Crit Rev 67 malignant ascites